Summer Symposium 2015

CANCER COMPLEXITY:
Heterogeneity in Tumor Progression and Drug Response

Symposium

The Koch Institute’s 14th annual Summer Symposium explored the genetic and epigenetic heterogeneity within tumors that yield diverse cancer phenotypes, such as drug resistance. Speakers highlighted the latest breakthroughs in overcoming clinical challenges in cancer diagnostics and therapy.

Speakers and Presentations

Stratton

Signatures of Mutational Processes in Human Cancer

Sir Michael Stratton, PhD
Director
Wellcome Trust Sanger Institute

View video (with opening remarks from Tyler Jacks and Michael Hemann)

Iacobuzio-Donahue

Genetic Features of Subclonal Evolution in Pancreatic Cancer

Christine A. Iacobuzio-Donahue, MD, PhD
Associate Director for Translational Research, David M. Rubenstein Center for Pancreatic Cancer Research
Memorial Sloan Kettering Cancer Center

View video

Swanton

Spatial and Temporal Dynamics of Tumour Evolution: Implications for Drug Development

Charles Swanton, MD, PhD
Professor
Francis Crick Institute and UCL Cancer Institute and Hospitals, UK

View video

Shaw

Tumor Heterogeneity and Drug Resistance

Alice Shaw, MD, PhD
Associate Professor, Department of Medicine, Harvard Medical School
Thoracic Cancer Program, Massachusetts General Hospital

Polyak

Breast Tumor Evolution

Kornelia Polyak, MD, PhD
Professor, Department of Medicine, Harvard Medical School
Department of Medical Oncology, Dana-Farber Cancer Institute 

Nolan

The Deeper Phenotypes of the Single Cell in Cancer and Immunity

Garry P. Nolan, PhD
Rachford and Carlota Harris Professor, Department of Microbiology & Immunology
Stanford University School of Medicine

View video

Pe'er

Navigating the Phenotypic Landscape of Tumor Heterogeneity at Single-Cell Resolution

Dana Pe'er, PhD
Associate Professor of Biology and Systems Biology
Columbia University

View video

Jacks

Engineering the Cancer Genome

Tyler Jacks, PhD
Director
David H. Koch Professor of Biology
Koch Institute at MIT

View video

Stegmaier

Pediatric Cancer and Genome Simplicity

Kimberly Stegmaier, MD
Co-Director, Pediatric Hematologic Maligancy Program, Dana-Farber Cancer Institute & Boston Children's Hospital
Associate Professor of Pediatrics, Harvard Medical School

View video

Stegmeier

High Complexity Barcoding to Study Clonal Dynamics in Response to Cancer Therapy

Frank Stegmeier, PhD
Director
Novartis Institutes for Biomedical Research

View video

Hemann

The Tumor Microenvironment Drives Heterogeneity in Therapeutic Response

Michael Hemann, PhD
Symposium Chair
Associate Professor of Biology
Koch Institute at MIT

View video (with closing remarks from Tyler Jacks)

Supporters

Affiliates

Baxalta US Inc
Janssen Research & Development, LLC
Takeda Oncology
Thermo Fisher Scientific

Collaborators

Agilent Technologies, Inc.
Amgen
Supported by an educational grant from AstraZeneca
Boehringer Ingelheim RCV GmbH & Co KG
Onkaido Therapeutics
Roche
Sanofi
Third Rock Ventures LLC

Sponsors

Alnylam Pharmaceuticals
Atlas Venture
Blueprint Medicines
Cell Signaling Technology, Inc.
Genentech, Inc., a Member of the Roche Group
Merrimack Pharmaceuticals
Mirna Therapeutics
Nature Medicine
Novartis Institutes for BioMedical Research

Vendors

BioLegend
Cell Press
Cell Signaling
EMD Millipore
Exiqon Inc
IDT
Proteinsimple
Qiagen Inc
Seahorse BioScience
Stemcell
Transnetyx